Business
Neomatrix Product Supply Agreement
Neomatrix Product Supply Agreement.
About this update from 4basebio Plc
[{"type":"text","content":"\n\n \n \n\n\n\n\n25 May 20234basebio PLC(\"4basebio\", the \"Company\" or the “Group”)4basebio and Neomatrix announce clinical material supply agreement to develop personalised cancer therapy utilising 4basebio’s proprietary hpDNA™.Cambridge, UK , 25 May 2023 – 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform, today announces a product supply agreement with Neomatrix, an Italian based biotech company focused on personalised cancer immunotherapies.Under the agreement, 4basebio will supply clinical and preclinical DNA materials into Neomatrix’ neoantigen cancer vaccine program. The program is expected to start patient enrolment in early 2024. Neomatrix will gain access to 4basebio‘s proprietary DNA products including hpDNA™ and oeDNA™. 4basebio will manufacture and provide the personalised clinical grade DNA products, the key component in Neomatrix’ immunotherapy cancer treatment. Neomatrix’ vaccine based cancer treatment utilises the patient’s immune system to recognise newly generated antigens (neoantigens), created by and displayed on tumour cells. Personalised cancer vaccines require a tumour biopsy which is sequenced to identify the neoantigens created by cancer-specific DNA mutations. A patient specific DNA sequence coding for such neoantigens is then designed, produced and administered. The time between initial biopsy and vaccine administration (“needle to needle”) is critical. 4basebio’s enzymatically produced synthetic DNA, with its rapid manufacturing timescales, is uniquely positioned to provide high performant DNA products in a timely fashion.Dr Heikki Lanckriet, CEO and CSO for 4basebio, said: “We are delighted to be working with Neomatrix in the delivery of neoantigen cancer vaccines. 4basebio’s DNA products offer significant advantages both in terms of performance and the time required to manufacture a personalised vaccine, which is particularly relevant where needle to needle time is paramount to clinical outcome.”Luigi Aurisicchio, CEO of Neomatrix, said: “We are excited to have 4basebio as our partner for the production of our personalised neoantigen vaccines. The performance and quality o...